Published on 11 May 2022 on Simply Wall St. via Yahoo Finance
As Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) drops to US$26m market cap, insiders might rethink...
The recent 14% drop in Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) stock could come as a blow to insiders who purchased US$2.7m worth of stock at an average buy price of US$3.28 over the past 12 months. This is not good as insiders invest based on expectations that their money will appreciate over time. However, as a result of recent losses, their original investment is now worth only US$489k.
While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.
See our latest analysis for Cyclerion Therapeutics